<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethionamide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethionamide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ethionamide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11208" href="/d/html/11208.html" rel="external">see "Ethionamide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13287" href="/d/html/13287.html" rel="external">see "Ethionamide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F168672"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trecator</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F168692"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antitubercular Agent</li></ul></div>
<div class="block doa drugH1Div" id="F168674"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c2940f0-014f-4362-aba1-d832529ab519">Tuberculosis, drug resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, drug resistant (alternative agent): Note:</b> Expert consultation for optimal regimen and duration of treatment is advised; coadministration of pyridoxine is recommended for prevention of neurotoxic effects.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 15 to 20 mg/kg/day in 1 or 2 divided doses (usually 250 or 500 mg once or twice daily) in combination with additional appropriate antituberculosis agents. Some experts recommend starting with 250 mg once daily and gradually increasing over 1 week; few patients tolerate 500 mg twice daily (maximum daily dose: 1 g/day) (ATS/CDC/ERS/IDSA [Nahid 2019]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990393"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in manufacturer's labeling; however, the following adjustments have been reported in the literature (ATS/CDC/IDSA [Nahid 2016]):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: 250 to 500 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) on hemodialysis: 250 to 500 mg/day.</p></div>
<div class="block doha drugH1Div" id="F50987544"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution (ATS/CDC/IDSA [Blumberg 2003]).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F168675"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F168686"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13287" href="/d/html/13287.html" rel="external">see "Ethionamide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d4ce8b9-c2d8-48d5-9347-306cae012c37">Active tuberculosis infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Active tuberculosis infection (excluding meningitis), treatment (second-line therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for detailed information<b>.</b> Always use as part of a multidrug regimen (ATS/CDC/IDSA [Nahid 2016]). Coadministration of pyridoxine is recommended for prevention of neurotoxic effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 to 20 mg/kg/day in divided doses once or twice daily (in HIV-exposed/-infected, divided doses three times daily have also been recommended); usual adult dose range: 250 to 500 mg/dose; maximum daily dose: 1,000 mg<b>/day</b>. <b>Note:</b> Ethionamide causes nausea and patients are often unable to tolerate the maximum dose divided twice daily (eg, in adults, 500 mg twice daily); therefore, experts suggest beginning with a low once daily dose and gradually increasing as tolerated; may consider therapeutic drug monitoring to aid in determining appropriate dose (ATS/CDC/IDSA [Nahid 2016]; HHS [OI pediatric 2020]; Seddon 2012).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109907"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer labeling nor recommendations specific for pediatric patients; experience in adult patients suggests that dosage adjustment may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51109908"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (Blumberg 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F168640"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions may be from combination antituberculosis regimens.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, acute generalized exanthematous pustulosis, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Goiter, gynecomastia, hypoglycemia, hypothyroidism, pellagra (pellagra-like syndrome), weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, metallic taste, nausea, sialorrhea, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, dizziness, drowsiness, headache, peripheral neuritis, psychiatric disturbance, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, optic neuritis</p></div>
<div class="block coi drugH1Div" id="F168653"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ethionamide or any component of the formulation; severe hepatic impairment</p></div>
<div class="block war drugH1Div" id="F168637"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Cases of severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms syndrome have been reported. Discontinue treatment immediately and institute appropriate therapy if signs or symptoms of SCAR develop.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may cause hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: May cause hepatotoxicity; monitor liver function tests at baseline and monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction; hypothyroidism (reversible; with and without goiter) has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Drug-resistant tuberculosis develops rapidly if ethionamide is used alone; must administer with other antituberculosis agents. Directly observed therapy (DOT) is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Avoid excessive ethanol intake; psychotic reaction may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Eye exams: Eye exams are recommended at baseline and periodically during therapy.</p></div>
<div class="block foc drugH1Div" id="F168646"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trecator: 250 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p></div>
<div class="block geq drugH1Div" id="F168633"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F2524566"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Trecator Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $6.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F168650"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Directly observed therapy is recommended. Administer with or without meals. GI adverse effects may be decreased by administration at meals or bedtime, decreased dose, or giving with antiemetics.</p></div>
<div class="block admp drugH1Div" id="F52612776"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals or at bedtime to decrease GI distress (nausea)</p></div>
<div class="block use drugH1Div" id="F168649"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Tuberculosis:</b> Treatment of tuberculosis (TB) disease (active TB), in combination with other antituberculosis agents, in patients with <i>Mycobacterium tuberculosis</i> resistant to isoniazid or rifampin, or when there is intolerance to other drugs.</p></div>
<div class="block mst drugH1Div" id="F58927924"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ethionamide may be confused with ethosuximide.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299299"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220232"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Ethionamide. Specifically, there may be a risk for a psychotic episode/reaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSERINE: Ethionamide may enhance the adverse/toxic effect of CycloSERINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May increase the serum concentration of Ethionamide. Ethionamide may increase the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54901887"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to treatment of multidrug resistant tuberculosis in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment for multidrug resistant tuberculosis (Esmail 2018).</p></div>
<div class="block pri drugH1Div" id="F168656"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies and limited human data, in utero exposure to ethionamide may cause fetal harm (HHS [OI 2020]). In addition, ethionamide may increase the risk of nausea and vomiting in pregnant patients (Esmail 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020) as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Data are limited for use of second line drugs during pregnancy (ie, ethionamide) (ATS/CDC/ERS/IDSA [Nahid 2019]). The treatment of multidrug resistant TB in pregnant patients should be individualized; evidence to support a specific regimen is not available (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020). Use of ethionamide should be avoided when possible (HHS [OI 2020]).</p></div>
<div class="block brc drugH1Div" id="F168657"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ethionamide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">If ethionamide is used while breastfeeding, monitor the infant for adverse effects. Patients with multidrug resistant tuberculosis and a sputum smear-positive test should avoid breastfeeding when possible (Esmail 2018).</p></div>
<div class="block dic drugH1Div" id="F168658"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Healthcare provider may recommend an increase in dietary intake of pyridoxine to prevent neurotoxic effects of ethionamide. Avoid alcohol.</p></div>
<div class="block mop drugH1Div" id="F168644"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and monthly serum ALT and AST; baseline and periodic ophthalmic exams; periodic blood glucose and TSH; signs and symptoms of severe cutaneous adverse reactions; ethionamide serum concentrations (when clinically indicated).</p></div>
<div class="block rer drugH1Div" id="F56556227"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Obtain samples at 2 and 6 hours post dose to detect delayed absorption or malabsorption (Peloquin 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic peak levels: 1 to 5 mcg/mL after a 250 to 500 mg dose (Peloquin 2002).</p></div>
<div class="block pha drugH1Div" id="F168636"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits peptide synthesis; bacteriostatic</p></div>
<div class="block phk drugH1Div" id="F168652"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Essentially complete absorption</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 93.5 L; widely distributed into body tissues and fluids including CSF</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~30% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Prodrug; extensively hepatic to active and inactive metabolites </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: ~1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;1% as unchanged drug; as active and inactive metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038613"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Trecator</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Farmanguinhos etionamida</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nicotion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Trecator</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ethatyl | Trecator</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trecator</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">E-thio | Ethide | Ethimax | Ethiobin | Ethiocid | Ethomid | Etomide | Etumide | Mycotuf | Myobid | Thiomid e</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ethimide | Ethinamin | Ethionamide yamanouchi | Itiocide | Sertinon | Teberus | Thioniden | Tubermin | Tuberoson</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ethomid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ethomid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ethiocol | Etionamida</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ethomid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Etionamid | Thiomid e | Trecator sc | Tumid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Trecator</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Etionamida | Trecator sc</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Etionamida atb</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ethomid | Etid | Myobid | Reginicid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Eton</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Trecator</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ethionamid | Ethomid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ethomid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ethatyl | Ethionamide macleods</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ethide | Ethomid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21085831">
<a name="21085831"></a>Arbex MA, Varella Mde C, de Siqueira HR, et al, "Antituberculosis Drugs: Drug Interactions, Adverse Effects, and Use in Special Situations. Part 2: Second-Line Drugs," <i>J Bras Pneumol</i>, 2010, 36(5):641-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/21085831/pubmed" id="21085831" target="_blank">21085831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588714">
<a name="12588714"></a>Blumberg HM, Burman WJ, Chaisson RE, et al, “American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,” <i>Am J Respir Crit Care Med</i>, 2003, 167(4):603-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/12588714/pubmed" id="12588714" target="_blank">12588714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19730409">
<a name="19730409"></a>Centers for Disease Control and Prevention (CDC), "Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children," <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/19730409/pubmed" id="19730409" target="_blank">19730409</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention, “Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,” <i>MMWR Recomm Rep</i>, 2003, 52(RR11);26, 64.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2769511">
<a name="2769511"></a>Donald PR and Seifart HI, “Cerebrospinal Fluid Concentrations of Ethionamide in Children With Tuberculous Meningitis,” <i>J Pediatr</i>, 1989, 115(3):483-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/2769511/pubmed" id="2769511" target="_blank">2769511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.<i> J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>. Accessed June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6368424">
<a name="6368424"></a>Pattyn SR, Janssens L, Bourland J, et al, “Hepatotoxicity of the Combination of Rifampin-Ethionamide in the Treatment of Multibacillary Leprosy,” <i>Int J Lepr Other Mycobact Dis</i>, 1984, 52(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/6368424/pubmed" id="6368424" target="_blank">6368424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12381217">
<a name="12381217"></a>Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. <i>Drugs</i>. 2002;62(15):2169-2183. doi:10.2165/00003495-200262150-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/12381217/pubmed" id="12381217" target="_blank">12381217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22983960">
<a name="22983960"></a>Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. <i>Am J Respir Crit Care Med</i>. 2012;186(10):953-964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/22983960/pubmed" id="22983960" target="_blank">22983960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7667049">
<a name="7667049"></a>Starke JR and Correa AG, “Management of Mycobacterial Infection and Disease in Children,” <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethionamide-drug-information/abstract-text/7667049/pubmed" id="7667049" target="_blank">7667049</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Trecator (ethionamide) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2020.</div>
</li>
<li>
<div class="reference">
                  Trecator (ethionamide) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published 2020. Accessed July 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9438 Version 169.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
